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Summary 
チロシンリン酸化による核内ErbB4 シグナルの制御 
先端生命科学専攻 ゲノム機能学講座 (分子細胞生物学研究室) 石橋 賢一 
 
【背景・目的】 
 チロシンキナーゼは、増殖や分化・接着・転写といった様々な細胞応答に関与し、受容体型と非受容
体型に分類される。受容体型チロシンキナーゼは細胞膜上に位置し、細胞外からの刺激を細胞内へ伝達
する。一方、非受容体型チロシンキナーゼは、細胞内局在により機能が大きく変化する。チロシンリン
酸化は、主に細胞質において起こることが知られているが、当研究室では核内にも非受容体型チロシン
キナーゼが局在し、機能していることを示唆してきた。 
 ErbB4 はEGFR (epidermal growth factor receptor) family に属する受容体型チロシンキナーゼで
あり、リガンド刺激により活性化した後に細胞質内が限定分解され 4ICD (ErbB4 intracellular 
domain) が生成する。4ICD は非受容体型チロシンキナーゼのように細胞質内に局在するが、核内に
移行して転写に関与することも報告されている。しかし、4ICD を介した核内シグナルのチロシンリン
酸化による制御は未解明であり、本研究において解析を行った。 
【方法・結果】 
1．ヒストンメチル化における核内 ErbB4 チロシンリン酸化の役割 
 ErbB4 を介した核内シグナルを調べるために、ErbB4 を高発現している細胞をリガンドである
NRG-1 (neuregulin-1) を用いて刺激した。NRG-1 刺激をしたところ、H3K9me3 (histone H3 
tri-methylated on Lys 9) の上昇とH4K16ac (histone H4 acetylated on Lys 16) の低下が観察され
た。H4K16ac の低下はEGFR のリガンドEGF 刺激によっても観察されたが、H3K9me3 の上昇は
観察されなかったことから、H3K9me3 の上昇には ErbB4 特異的なシグナルが関与していると考え
た。そこで、核内ErbB4 シグナルの影響を調べるために 4ICD 生成をDAPT により阻害したところ、
H3K9me3 の上昇も抑制された。 
さらに核内の 4ICD の影響を調べる 
ために核移行シグナルNLS (nuclear 
 localization signal) を付加した 
NLS-4ICD を作製した。NLS-4ICD 
は 4ICD と比較して強く核内に局在 
し、大きくH3K9me3 を上昇させた。 
また、キナーゼ活性を欠損させた 
変異体NLS-4ICD(KD) (kinase-dead) 
と比較した結果、NLS-4ICD は 
NLS-4ICD(KD) よりも強く 
H3K9me3 を上昇させたことから、 
H3K9me3 の上昇には 4ICD の核内 
 
 
Fig. 1. 核内ErbB4 チロシンリン酸化によるH3K9me3 の上昇 
(A) 核移行型4ICD (NLS-4ICD) とキナーゼ活性を欠損させた変異体NLS-4ICD(KD)
のH3K9me3への影響. (B) H3K9me3 蛍光強度の定量. ***p<0.001. 
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チロシンリン酸化反応が関与していることが示唆された (Fig. 1)。 
2．核内 ErbB4 シグナルの c-Src による抑制 
1) EGF 刺激の核内ErbB4 シグナルへの影響 
 EGFR family やリガンドの発現量は、分化や増殖の過程において巧妙に調節されている。そこで、
EGFR family 内において相互にシグナルを調節しあっているのではないかと考え、ErbB4 シグナル
に対する他の EGFR family の影響について調べた。EGF 刺激により EGFR を活性化させた状態で
は、NRG-1  刺激により H3K9me3 が上昇しないことを見出した。また、EGF 刺激は NRG-1 刺激
による細胞増殖抑制も阻害することが分かった。このことから、NRG-1 により活性化されたErbB4 シ
グナルが同じ family に属する EGFR により抑制されることが示唆された。さらに、EGFR による
ErbB4 シグナルの抑制について詳しく調べた。EGFR の下流分子である Src チロシンキナーゼを阻
害したところ、EGF 刺激によるErbB4 シグナルの抑制が解除され、NRG-1 刺激によりH3K9me3 の
上昇が見られた。Src の関与を強めるために、Src がノックアウトされた SYF 細胞と、SYF 細胞に
c-Src を発現させた SYF/c-Src 細胞を用いて実験を行った。SYF 細胞に ErbB4 を遺伝子導入し
NRG-1 刺激を行ったところ H3K9me3 の上昇が見られたが、SYF/c-Src 細胞では上昇が見られなか
った。この結果から、EGF 刺激により活性化した c-Src が核内 ErbB4 シグナルを抑制していること
が示唆された。 
2) 4ICD 核内移行のc-Src による抑制 
 次に、c-Src による核内ErbB4 シグナルの抑制 
機構について解析を行った。SYF/c-Src 細胞では 
NRG-1 刺激により核内のErbB4 の染色強度が上昇 
していなかったことから、4ICD の核内移行の制御に 
c-Src が関与しているのではないかと考えた。そこで、 
4ICD と c-Src を共発現させたところ、4ICD の核内 
移行が抑制された (Fig. 2)。また、c-Src による 4ICD 
の核内移行抑制はSrc 阻害剤により減弱した。さらに、 
c-Src の 4ICD に対する影響を調べたところ、c-Src 
の活性に依存した 4ICD のチロシンリン酸化の亢進と c-Src と 4ICD の相互作用が観察された。c-Src 
による 4ICD チロシンリン酸化の影響を調べるため、チロシン残基をフェニルアラニンに置換し、リ
ン酸化が起こらないYF変異体を作製した。4ICD と比較し、4ICD Y950F/Y1056F 変異体では c-Src 
との相互作用が低下した。また、c-Src による核内移行の抑制も低下していた。さらに、4ICD 
Y950F/Y1056F 変異体は 4ICD よりも強く H3K9me3 を上昇させた。以上の結果から、4ICD を介
した核内ErbB4 シグナルは、c-Src を介した 4ICD のチロシンリン酸化と核内移行の抑制により制御
されていることが分かった。 
3．転写における核内 ErbB4 シグナルの影響 
 hTERT (human telomerase reverse transcriptase) の転写はプロモーター領域におけるH3K9me3 
とH3K27me3 レベルによって調節されると報告されている。そこで、ErbB4 シグナルがどのように
 
Fig. 2. c-Src による 4ICD 核内移行の抑制 
c-Src の共発現により4ICD の核内移行が抑制された.  
N: 核, Cyto: 細胞質. Bars, 10 µm. 
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hTERT の転写を調節しているかについて調べた。半定量的RT-PCR により解析したところ、hTERT 
の転写はNRG-1 刺激により低下し、EGF 刺激により低下が抑制された。さらに、NRG-1 とEGF 刺
激下において Src を阻害したところ、再び hTERT の転写が低下した。hTERT の転写抑制における
核内ErbB4 シグナルの関与を強めるために、hTERT 転写抑制における 4ICD 生成の影響を調べた。
その結果、4ICD 生成阻害によりhTERT の転写抑制も阻害された。また、NLS-4ICD の発現によっ
ても hTERT の転写が低下したことから、ErbB4 を介した核内シグナルがhTERT の転写抑制に関与
していることが示唆された。加えて、H3K27me3 はNLS-4ICD の発現により低下していたことから、
核内 ErbB4 シグナルの調節による H3K9me3 レベルの変化が、hTERT の転写において重要な働き
をしていると考えられる。 
【総括】 
 本研究の結果から、核内ErbB4 シグナ 
ルによりH3K9me3 が上昇することが明 
らかとなった (Fig. 3A)。また、H3K9me3 
の上昇には 4ICD の核内チロシンリン酸化 
反応が関与していることも示唆した。 
H3K9のトリメチル化にはSETDB1 や 
SUV39H1 といったヒストンメチル化酵素 
が関与すると報告されており、4ICDを 
介した核内チロシンリン酸化反応により 
ヒストンメチル化酵素の機能が調節されて 
いると考えられる。 
 ヒストンメチル化への関与に加えて、核内ErbB4 シグナルが c-Src を介したチロシンリン酸化によ
って抑制されることも見出した (Fig. 3B)。また、細胞の増殖や分化に関与する hTERT の転写も
NRG-1/ErbB4 シグナルと EGF/EGFR/c-Src シグナルにより調節されていたことから、ErbB4・
EGFR・c-Src のシグナルバランスによって細胞の増殖や分化が制御されていると考えられる。今後、
ヒストン修飾や転写に関与するErbB4 の核内チロシンリン酸化基質を探索することにより、細胞の増
殖や分化のメカニズムが明らかになると考えている。 
【参考論文】 
1) Ishibashi, K., Fukumoto, Y., Hasegawa, H., Abe, K., Kubota, S.-i., Aoyama, K., Kubota, S., Nakayama, Y., 
and Yamaguchi, N.: Nuclear ErbB4 signaling through H3K9me3 that is antagonized by EGFR-activated 
c-Src.  J. Cell Sci., in press, 2012, doi: 10.1242/jcs.116277. 
2) Aoyama, K., Fukumoto, Y., Ishibashi, K., Kubota, S., Morinaga, T., Horiike, Y., Yuki, R., Takahashi, A., 
Nakayama, Y., and Yamaguchi, N.: Nuclear c-Abl-mediated tyrosine phosphorylation induces chromatin 
structural changes through histone modifications that include H4K16 hypoacetylation. Exp. Cell Res., 317: 
2874-2903, 2011. 
3) Fukumoto, Y., Obata, Y., Ishibashi, K., Tamura, N., Kikuchi, I., Aoyama, K., Hattori, Y., Tsuda, K., 
Nakayama, Y., and Yamaguchi, N.: Cost-effective gene transfection by DNA compaction at pH 4.0 using 
acidified, long shelf-life polyethylenimine. Cytotechnology, 62: 73-82, 2010.  
 
 
Fig. 3. 核内ErbB4 シグナルのチロシンリン酸化を
介した制御モデル 
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Introduction 
 
     Protein-tyrosine kinases are found in multicellular organisms and have important roles in a 
variety of the intracellular signal transduction pathways, which are critical in the control of cellular 
processes, such as cell proliferation, differentiation, gene expression, cell adhesion, and metabolic 
changes (Hubbard and Till, 2000). Receptor-type tyrosine kinases, a subclass of 
transmembrane-spanning receptor, transmit signals across the plasma membrane from 
extracellular milieus to the inside of cells (Ullrich and Schlessinger, 1990). On the other hand, the 
function of non-receptor-type tyrosine kinases depends upon their intracellular localization (Neet 
and Hunter, 1996). Although tyrosine phosphorylation is mainly associated with cytoplasmic 
events, some types of tyrosine kinases and phosphatases localize within the nucleus and nuclear 
tyrosine phosphorylation may play a role in nuclear events (Cans et al., 2000; Moorhead et al., 
2007). We have shown that Lyn, a member of non-receptor-type Src-family tyrosine kinases (SFKs), 
is imported into and rapidly exported from the nucleus (Ikeda et al., 2008), and nuclear tyrosine 
phosphorylation by SFKs, Csk and c-Abl has a role in changes of chromatin structure and histone 
modification (Yamaguchi et al., 2001; Nakayama and Yamaguchi, 2005; Takahashi et al., 2009; 
Aoyama et al., 2011). 
     The ErbB receptor tyrosine kinases comprise the four members, EGFR/ErbB1, HER2/ErbB2, 
ErbB3 and ErbB4. ErbB-family members are known to play critical roles in regulating cell 
proliferation, differentiation, apoptosis and migration (Yarden and Sliwkowski, 2001). Each of the 
receptors is a type I transmembrane protein and composed of : (i) an extracellular domain that 
provides a ligand-binding site, (ii) a single transmembrane domain and (iii) an intracellular domain 
that encodes a tyrosine kinase catalytic domain and a C-terminal region. The cytoplasmic domain 
contains multiple tyrosine residues (Schulze et al., 2005), and the receptor function is regulated by 
tyrosine phosphorylation. For instance, EGFR signaling is positively regulated by SFKs through 
tyrosine phosphorylation (Dittmann et al., 2008; Iida et al., 2012). 
ErbB4 is known to have a unique signaling feature among the ErbB-family members. Stimulation 
with NRG-1, a ligand of ErbB4, not only activates downstream signaling molecules close to or on 
the cytoplasmic face of the plasma membrane but also cleaves the ErbB4 extracellular domain and 
the intracellular domain by TNF-α-converting enzyme (TACE) and γ-secretase, respectively (Rio et 
al., 2000; Ni et al., 2001). Cleavage by TACE removes the extracellular domain and leaves the 
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membrane-associated 80-kDa ErbB4 fragment (m80 ErbB4). The m80 ErbB4 fragment is further 
cleaved by γ-secretase to release the soluble 80-kDa ErbB4 fragment, termed the ErbB4 
intracellular domain (4ICD), into the cytoplasm. Then, 4ICD acts as a non-receptor-type tyrosine 
kinase and can shuttle between the cytoplasm and the nucleus. It is evident that 4ICD can signal 
directly to the nucleus to regulate transcription (Ni et al., 2001; Carpenter, 2003; Williams et al., 
2004; Sardi et al., 2006). Despite the existence of multiple tyrosine phosphorylation sites on 4ICD 
(Kaushansky et al., 2008), the regulation of 4ICD nuclear signaling through tyrosine 
phosphorylation is poorly understood. 
     In this study, we investigate ErbB4-mediated nuclear signaling upon stimulation with NRG-1. 
Generation of 4ICD increases the levels of H3K9me3, which is antagonized by EGF-activated 
EGFR, another member of the ErbB family. We further identify activated c-Src downstream of 
EGFR as a negative regulator of nuclear ErbB4 signaling. Our findings demonstrate that tyrosine 
phosphorylation of 4ICD by EGFR-activated c-Src plays an inhibitory role in nuclear ErbB4 
signaling. 
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Results 
 
ErbB4-increased H3K9me3 levels following NRG-1 stimulation 
To examine the role of ErbB4 signaling in the nucleus, T47D breast cancer cells were 
stimulated with NRG-1. We observed that endogenous ErbB4 was activated at 5 min and 
subsequent 4ICD release was peaked at 30 min after NRG-1 stimulation (Fig. 1A), consistent with 
previous observations (Ni et al., 2001). NRG-1 stimulation was found to decrease high-intensity 
areas (red and yellow) and increase low-intensity areas (green and blue) of DNA staining, leading 
to an increase in nucleus size (Fig. 1B). Upon NRG-1 stimulation, treatment with AG1478, an 
EGFR and ErbB4 inhibitor (Egeblad et al., 2001), blocked NRG-1-induced 4ICD release and an 
increase in nuclear size (supplementary material Fig. S1A,B). Since NRG-1 stimulation did not 
induce BrdU incorporation (supplementary material Fig. S1C), the increase in nuclear size may be 
not due to DNA synthesis but rather chromatin structural changes.  
We next examined histone modifications, because the regulation of chromatin structure is 
known to involve changes of histone modifications, such as methylation and acetylation (Jenuwein 
and Allis, 2001; Aoyama et al., 2011). Intriguingly, unlike trimethylated histone H3 on lysine 4 
(H3K4me3) and acetylated histone H4 on lysine 16 (H4K16ac), the levels of H3K9me3 in T47D 
cells were increased by NRG-1 stimulation of ErbB4 but decreased by EGF stimulation of EGFR 
(Fig. 1C; supplementary material Fig. S1D). NRG-1 stimulation was also found to increase 
H3K9me3 levels in ErbB4-transfected COS-1 cells (supplementary material Fig. S2A). These 
results suggest that ErbB4 and EGFR, both of which are members of the ErbB-family, have 
opposing effects on H3K9me3. 
 
Role of nuclear accumulation and the kinase activity of 4ICD in NRG-1-increased H3K9me3 
4ICD has one functional nuclear localization signal (NLS) and three putative nuclear export 
signals, and can shuttle between the cytoplasm and the nucleus (Ni et al., 2001; Williams et al., 
2004). We asked whether an ErbB4-mediated increase of H3K9me3 involved the release of 4ICD 
and its nuclear translocation. When treatment with DAPT prevented γ-secretase processing of 
ErbB4 and accumulated the membrane-associated 80-kDa ErbB4 fragment (m80 ErbB4) (Fig. 2A; 
Määttä et al, 2006; Sardi et al, 2006; Paatero et al., 2012), we examined the effect of 4ICD 
generation on H3K9me3 levels. Fig. 2B shows that DAPT treatment blocked the NRG-1-induced 
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increase of H3K9me3 levels, suggesting that 4ICD release has a critical role in NRG-1-increased 
H3K9me3 levels. Next, to examine whether nuclear translocation of 4ICD increased H3K9me3 
levels, we constructed NLS-4ICD by linking an additional NLS to the amino-terminus of 4ICD (Fig. 
2C). When 4ICD and NLS-4ICD were expressed in COS-1 cells, NLS-4ICD was mainly localized in 
the nucleus and the levels of H3K9me3 were much higher in cells expressing NLS-4ICD than those 
expressing 4ICD (Fig. 2D). Furthermore, to examine the effect of the kinase activity on H3K9me3, 
we compared NLS-4ICD with the kinase-dead mutant NLS-4ICD(KD) and an irrelevant 
NLS-tagged Src tyrosine kinase (NLS-Src) (Fig. 2C). Although similar levels of nuclear localization 
were observed among NLS-4ICD, NLS-4ICD(KD), and NLS-Src (supplementary material Fig. S2B; 
Fig. 2F), the tyrosine-phosphorylated band pattern induced by NLS-4ICD was somewhat different 
from that induced by NLS-Src (Fig. 2E). Notably, H3K9me3 levels were much higher in cells 
expressing NLS-4ICD than those expressing NLS-4ICD(KD) or NLS-Src (Fig. 2F,G). In contrast to 
H3K9me3, H3K4me3 levels in cells expressing NLS-4ICD were comparable to those in cells 
expressing NLS-4ICD(KD) or NLS-Src (Fig. 2G). These results suggest that nuclear translocation 
of 4ICD is critical for an increase of H3K9me3 levels in a manner dependent on 4ICD kinase 
activity. 
 
Inhibition of NRG-1-increased H3K9me3 by EGFR-activated Src 
ErbB4 activation decreases cell proliferation and induces differentiation, whereas the other 
ErbB-family members are involved in cell proliferation and survival (Yarden and Sliwkowski, 2001; 
Sardi et al, 2006). Given that NRG-1 and EGF bind to ErbB4 and EGFR, respectively (Linggi and 
Carpenter, 2006), expression levels of NRG-1 and EGF are well controlled in developing mammary 
glands (Schroeder and Lee, 1998). We thus hypothesized that H3K9me3 levels may be controlled by 
signal balance between ErbB4 and EGFR. To test this hypothesis, cells were costimulated with 
NRG-1 plus EGF. As a result, NRG-1-increased H3K9me3 levels were decreased by concomitant 
stimulation with EGF (Fig. 3A). In addition, inhibition of cell proliferation by NRG-1 was 
substantially rescued by EGF stimulation (Fig. 3B). However, the effect of EGF on 
NRG-1-repressed cell proliferation was diminished after 4 days of stimulation (Fig. 3B), because 
EGF stimulation decreased expression levels of EGFR in a 4-day stimulation period 
(supplementary material Fig. S3; Dikic and Giordano, 2003). Furthermore, concomitant 
stimulation with EGF and NRG-1 was incapable of inhibiting NRG-1-induced ErbB4 activation 
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and 4ICD release (Fig. 3C). Taken together, these results suggest that EGFR activation blocks 
intracellular ErbB4 signaling toward an increase of H3K9me3 and growth inhibition. 
It is known that the binding of EGF to EGFR activates SFKs, ERK1/2, and PI3K 
(supplementary material Fig. S1D; Yarden and Sliwkowski, 2001). To ask whether activation of 
SFKs, ERK1/2, or PI3K is required for EGFR-mediated inhibition of ErbB4 signaling, we treated 
cells with PP2 (SFK inhibitor), U0126 (MEK1/2 inhibitor), and wortmannin (PI3K inhibitor). In 
sharp contrast to U0126 and wortmannin, PP2 treatment increased H3K9me3 levels upon 
costimulation with NRG-1 plus EGF (supplementary material Fig. S4A; Fig. 3D). A similar effect of 
SU6656 (another SFK inhibitor; Blake et al., 2000) was seen upon costimulation with NRG-1 plus 
EGF (supplementary material Fig. S4B). To scrutinize the role of SFKs (e.g. c-Src, c-Yes, Fyn, and 
Lyn) in EGFR-mediated inhibition of ErbB4 signaling, we used embryonic fibroblast SYF cells, 
which are genetically deficient in expression of c-Src, c-Yes and Fyn and are undetectable in 
expression of Lyn (Klinghoffer et al., 1999), and the add-back version of SYF cells expressing active 
c-Src (SYF/c-Src cells) (supplementary material Fig. S5A; Takahashi et al., 2009). ErbB4 activation 
by NRG-1 increased H3K9me3 levels in ErbB4-transfected SYF cells but could not increase those 
in ErbB4-transfected SYF/c-Src cells (Fig. 3E, top and middle). Note that high levels of H3K9me3 
were observed in SYF cells exhibiting increased levels of nuclear ErbB4 (supplementary material 
Fig. S5C) and that in SYF/c-Src cells, NRG-1 stimulation did not increase levels of nuclear ErbB4 
and H3K9me3 (Fig. 3E, bottom; supplementary material Fig. S5C). To further examine whether 
the kinase activity of c-Src affected nuclear translocation of 4ICD, COS-1 cells were cotransfected 
with 4ICD and c-Src. Although c-Src was mainly localized to the cytoplasm (supplementary 
material Fig. S5D; Kasahara et al., 2007a), c-Src expression inhibited nuclear localization of 4ICD 
and SU6656 treatment recovered the levels of 4ICD’s nuclear localization (Fig. 3F), suggesting the 
inhibitory role of c-Src kinase activity in nuclear translocation of 4ICD. 
 
Role of Tyr950 and Tyr1056 on 4ICD in blockade of 4ICD nuclear signaling by c-Src 
Since phosphorylation of EGFR by activated SFKs changes subcellular localization and 
functions of EGFR (Stover et al., 1995; Dittmann et al., 2008; Iida et al., 2012), we examined 
whether 4ICD was phosphorylated by c-Src. When COS-1 cells were cotransfected with 4ICD and 
c-Src, expression of c-Src increased the levels of tyrosine phosphorylation of 4ICD and SU6656 
treatment obviously inhibited c-Src-induced 4ICD phosphorylation (Fig. 4A, bottom). Intriguingly, 
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4ICD was coimmunoprecipitated with c-Src in a manner dependent on c-Src kinase activity (Fig. 
4A, bottom). We next examined the role of Tyr950 (highly conserved among all ErbB-family 
members) and Tyr1056 (unique to ErbB4; Carpenter, 2003) on 4ICD in association of 4ICD with 
c-Src and nuclear translocation of 4ICD. Mutation at Tyr950 and Tyr1056 to Phe (Y950F/Y1056F) 
greatly decreased association of 4ICD with c-Src (Fig. 4B,C), and this Y950F/Y1056F mutant failed 
to induce c-Src-mediated inhibition of 4ICD’s nuclear translocation (Fig. 4D). However, it was 
difficult to evaluate the contribution of Y950F and Y1056F to the c-Src-mediated 4ICD 
phosphorylation sites, because ErbB4 has at least 19 potential sites of tyrosine phosphorylation 
(Kaushansky et al., 2008). Nonetheless, high accumulation of Y950F/Y1056F in the nucleus was 
found to induce high levels of H3K9me3 (Fig. 4E). These results suggest that phosphorylation of 
Tyr950 and Tyr1056 on 4ICD by c-Src mediates the association of 4ICD with c-Src, thereby 
inhibiting nuclear translocation of 4ICD. In other words, unphosphorylated 4ICD at Tyr950 and 
Tyr1056 translocates into the nucleus and increases H3K9me3 levels. 
 
NRG-1-repressed hTERT gene expression antagonized by EGF stimulation 
The hTERT is involved in cell proliferation and differentiation (Poole et al., 2001), and 
silencing of the hTERT gene involves repressive histone modifications, i.e., H3K9me3 and 
H3K27me3, in its promoter region (Zinn et al., 2007; Chen et al., 2012). To examine how the 
signaling pathways via ErbB4 and EGFR affected gene expression of hTERT, we analyzed the 
expression levels of the hTERT mRNA in T47D cells stimulated with none, NRG-1, EGF, or NRG-1 
plus EGF for 4 days. Semiquantitative RT-PCR analyses showed that the levels of hTERT gene 
expression were dramatically decreased in cells stimulated with NRG-1 but costimulation with 
NRG-1 plus EGF failed to increase the levels of hTERT gene expression (Fig. 5A). The results could 
be explained by a decrease in expression of EGFR on day 4 after EGF stimulation (supplementary 
material Fig. S3). We then examined the effects of ErbB4 and EGFR on hTERT gene expression 
after 30 min of stimulation, because stimulation with EGF for 30 min did not decrease the levels of 
EGFR (supplementary material Fig. S1D) and inhibited NRG-1-increased H3K9me3 levels (Fig. 
3A,D; supplementary material Fig. S4B). It is worthy of note that NRG-1 stimulation for 30 min 
actually decreased hTERT gene expression, and that costimulation with NRG-1 plus EGF for 30 
min could restore the levels of hTERT gene expression to those seen in unstimulated cells (Fig. 5B). 
In the presence of SU6656, costimulation with NRG-1 plus EGF for 30 min again decreased the 
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levels of hTERT gene expression. In addition, we analyzed the expression levels of breast cancer 1 
(BRCA1), which decreases hTERT gene expression (Li et al., 2002) and is increased by prolonged 
NRG-1 stimulation through the ErbB4-JNK pathway (Muraoka-Cook et al., 2006). Since NRG-1 
alone and NRG-1 plus EGF consistently increased BRCA1 gene expression on day 4 after 
stimulation (supplementary material Fig. S6), the increased levels of BRCA1 may be involved in 
repression of hTERT gene expression (Fig. 5A). However, stimulation with NRG-1 for 30 min did 
not increase the expression levels of BRCA1 (Fig. 5B), suggesting that NRG-1-repressed hTERT 
gene expression inhibitable by EGF-activated Src does not involve an increase in expression of 
BRCA1. 
To further substantiate transcriptional repression of hTERT by nuclear 4ICD, the levels of 
hTERT gene expression were examined in the presence or absence of DAPT. Treatment with DAPT 
blocked NRG-1-induced repression of hTERT gene expression (Fig. 5C). We then analyzed the 
levels of hTERT gene expression in NLS-4ICD-expressing HeLa S3 cells, which exhibit increased 
levels of H3K9me3 and decreased levels of H3K27me3 (Fig. 5D-F), and showed that the levels of 
hTERT gene expression were decreased upon NLS-4ICD expression (Fig. 5G). Taken together, 
these results suggest that repression of hTERT gene expression through nuclear ErbB4 signaling is 
negatively regulated by EGFR-activated Src. 
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Discussion 
 
In the present study, we show that ErbB4 activation by NRG-1 induces an increase of H3K9me3 levels and 
transcriptional repression of hTERT. NRG-1 stimulation activates ErbB4 and releases 4ICD from the cytoplasm to 
the nucleus. 4ICD-mediated nuclear tyrosine phosphorylation is involved in increased H3K9me3 levels, repression 
of hTERT gene expression, and inhibition of cell proliferation. We further show that co-activation of ErbB4 and 
EGFR by NRG-1 and EGF, respectively, blocks 4ICD nuclear signaling. It is of note that EGFR activation does not 
inhibit ErbB4 activation and 4ICD release. Rather, c-Src activated by EGFR inhibits nuclear translocation of 4ICD 
in a manner dependent on c-Src kinase activity. We can illustrate a model of the mechanism for the antagonizing 
effect of EGF to NRG-1-induced signaling toward histone modification and gene expression as well (Fig. 6A,B). 
The two tyrosine residues, Tyr950 and Tyr1056, on 4ICD are critical for association of 4ICD with c-Src, leading to 
inhibition of 4ICD’s nuclear translocation and subsequent blockade of 4ICD nuclear signaling. Regulation of 
ErbB4-mediated nuclear signaling by c-Src-mediated tyrosine phosphorylation plays an important role in changes 
of histone modification and gene expression. It is therefore intriguing to note that the two ErbB-family members 
ErbB4 and EGFR have opposing effects on nuclear signaling. 
It is well known that non-receptor-type tyrosine kinases act as co-transducers of transmembrane signals 
emanating from a variety of receptors, including receptor-type tyrosine kinases (Neet and Hunter, 1996). c-Src is a 
signal transducer of EGFR, and EGFR-activated c-Src enhances EGFR signaling through phosphorylation of 
tyrosine residues in the cytoplasmic region of EGFR (Biscardi et al., 1999; Dittmann et al., 2008). In addition to 
c-Src, the other SFK members c-Yes and Lyn are involved in nuclear translocation of EGFR and the binding of 
EGFR to the promoter region of target genes, such as B-Myb and iNOS (Iida et al., 2012), suggesting that SFKs are 
positive regulators of EGFR signaling. In sharp contrast, our results indicate that activated c-Src antagonizes 
nuclear ErbB4 signaling. NRG-1-increased H3K9me3 is decreased by concomitant stimulation with EGF, and 
treatment with PP2 or SU6656 increases H3K9me3 levels upon costimulation with NRG-1 plus EGF (Fig. 3D; 
supplementary material Fig. S4). Furthermore, NRG-1 stimulation increases H3K9me3 levels in SYF cells 
transfected with ErbB4, whereas it cannot increase H3K9me3 levels in c-Src-expressing SYF cells (SYF/c-Src) 
transfected with ErbB4 (Fig. 3E). Importantly, hTERT gene expression is repressed by NRG-1 stimulation through 
4ICD release, which is blocked by EGF stimulation through Src kinase activity (Fig. 5B,C). These results indicate 
that c-Src inhibits the nuclear ErbB4 signaling pathway for an increase of H3K9me3 and repression of hTERT 
gene expression. 
Although Src kinase activity does not affect 4ICD cleavage (Fig. 3C), c-Src inhibits nuclear accumulation of 
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4ICD in a manner dependent on its kinase activity (Fig. 3E,F; supplementary material Fig. S5C). Mutational 
analyses reveal that Tyr950 and Tyr1056 on 4ICD are involved in association of 4ICD with c-Src and inhibition of 
4ICD’s nuclear translocation (Fig. 4A-D). Furthermore, expression of NLS-4ICD greatly increases H3K9me3 
levels and represses hTERT gene expression (Fig. 2C-G; Fig. 5D,E,G), suggesting that nuclear accumulation of 
4ICD has a critical role in NRG-1-increased H3K9me3 levels and gene repression of hTERT. 
Despite the involvement of nuclear 4ICD in gene expression (Fig. 5D; Williams et al., 2004; Sardi et al., 
2006; Zhu et al., 2006), it is still unclear how tyrosine phosphorylation by nuclear ErbB4 is involved in gene 
expression through histone modifications. Recent studies show that H3K9me3 is controlled by histone 
methyltransferases and histone demethylases (Kouzarides, 2007). Although 4ICD is known to interact with 
Krab-associated protein 1 (KAP1), which can associate with the H3K9-methyltransferase SETDB1, the interaction 
of 4ICD with KAP1 is independent of its kinase activity and KAP1 phosphorylation by 4ICD has not been detected 
thus far (Schultz et al., 2002; Gilmore-Hebert et al., 2010). A small increase of H3K9me3 levels in cells expressing 
NLS-4ICD(KD) may be explained by the interaction of 4ICD with KAP1 (Fig. 2F,G). In addition to an increase of 
H3K9me3, a decrease of H3K27me3 levels was observed upon NLS-4ICD expression (Fig. 5F; supplementary 
material Fig. S7). H3K27 is trimethylated by the histone methyltransferase Ezh2, which is recruited by STAT5 at 
the intronic enhancer of the immunoglobulin k-chain complex to repress gene expression (Mandal et al., 2011). 
Since 4ICD is known to interact with STAT5 (Williams et al., 2004), it is likely that 4ICD has the potential to 
control H3K27me3 levels. Furthermore, our recent studies showed that nuclear tyrosine phosphorylation is in fact 
involved in chromatin structural changes and histone modifications (Yamaguchi et al., 2001; Nakayama and 
Yamaguchi, 2005; Takahashi et al., 2009; Aoyama et al., 2011). It was also reported that histone H3 is 
tyrosine-phosphorylated by Janus kinase 2, a non-receptor-type tyrosine kinase (Dawson et al., 2009). Taken 
together, these results provide evidence that nuclear tyrosine phosphorylation by nuclear-localized tyrosine kinases, 
including 4ICD, has important roles in histone modifications and gene expression. 
Why does c-Src have opposing effects on ErbB4 and EGFR signalings? Although c-Src inhibits 4ICD’s 
nuclear translocation through phosphorylation of Tyr950 and Tyr1056 on 4ICD (Fig. 3F; Fig. 4D), nuclear 
accumulation of EGFR is increased by c-Src (Dittmann et al., 2008). Phosphorylation of Y1101 on EGFR by the 
SFK members c-Yes and Lyn promotes nuclear translocation of EGFR (Iida et al., 2012). The ErbB-family 
members show high homology in the kinase domain (59-81% identity), whereas their divergent C-terminal regions 
are not conserved (11-25% identity) (Schulze et al., 2005). Given that Y1056 on ErbB4 and Y1101 on EGFR are 
located in their C-terminal regions, Y1056 unique to ErbB4 is not conserved among ErbB members but Y950 
present in the ErbB4 kinase domain is conserved among all of them. We assume that the nuclear-cytoplasmic 
14 
 
distribution of ErbB-family members is largely controlled by phosphorylation of the particular tyrosine residues on 
their cytoplasmic C-terminal domains. In addition, we have shown that the trafficking pathway of c-Src is different 
from those of c-Yes and Lyn, and differential trafficking of SFKs is specified by the state of palmitoylation in the 
Src homology 4 domain (Kasahara et al., 2004; Sato et al., 2009; Obata et al., 2010). These results raise the 
intriguing possibility that the role of each ErbB member could be modulated by individual SFK member-specific 
tyrosine phosphorylation of their cytoplasmic C-terminal domains. 
The expression levels of the ErbB members and their ligands are dynamically changed in mammary gland 
development. During pregnancy where differentiation and development of mammary glands actively take place 
(Robinson et al., 1995), transcriptional levels of ErbB4 and NRG-1 are increased and in return those of EGF are 
repressed (Schroeder and Lee, 1998). On lactation after pregnancy, transcriptional levels of NRG-1 are contrariwise 
repressed and those of EGF are increased (Schroeder and Lee, 1998). Furthermore, impaired differentiation and 
lactational failure were observed in ErbB4-deficient mice (Long et al., 2003). Given that overexpression of c-Src 
inhibits mammary epithelial cell differentiation (Jehn et al., 1992), we assume that the interplay of the 
NRG-1-ErbB4 signaling with the EGF-EGFR-c-Src signaling is important for the regulation of cell proliferation 
and differentiation. In addition, cell proliferation involves hTERT activity but low-level expression of hTERT 
relates to cell differentiation (Smith et al., 2003). High-level expression of hTERT, involved in cell transformation 
and carcinogenesis (Elenbaas et al., 2001), has been shown to correlate with poor differentiation and poor prognosis 
for a number of cancers, including neuroblastoma, acute myelogenous leukemia, and breast cancer (Poole et al., 
2001). Taken together with our findings that nuclear ErbB4 signaling is involved in repression of hTERT gene 
expression (Fig. 5), exploration of ErbB4-mediated signaling may contribute to development of new therapeutic 
strategies for cancers. 
In conclusion, we show for the first time that nuclear ErbB4 signaling is involved in an increase of 
H3K9me3 and transcriptional repression of hTERT, both of which are antagonized by EGFR-activated c-Src, and 
the signal balance between ErbB4 and EGFR may be important for cell proliferation and differentiation. It would 
be interesting to determine how c-Src inhibits nuclear translocation of 4ICD and to identify substrates downstream 
of 4ICD. Further studies will contribute to a better understanding of the regulation of nuclear ErbB4 signaling 
through tyrosine phosphorylation. 
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Conclusion 
 
The ErbB family of receptor tyrosine kinases comprises four members: EGFR (epidermal growth 
factor receptor) /ErbB1, HER2/ErbB2, ErbB3 and ErbB4, and plays roles in signal transduction at 
the plasma membrane upon ligand stimulation. Stimulation with neuregulin-1 (NRG-1) cleaves 
ErbB4 and releases the ErbB4 intracellular domain (4ICD) that translocates into the nucleus to 
control gene expression. However, little is known about the regulation of 4ICD nuclear signaling 
through tyrosine phosphorylation. We show here that 4ICD nuclear signaling is antagonized by 
EGF-induced c-Src activation via EGFR. Generation of 4ICD by NRG-1 leads to increased levels of 
trimethylated histone H3 on lysine 9 (H3K9me3) in a manner dependent on 4ICD’s nuclear 
accumulation and its tyrosine kinase activity. Once EGF activates c-Src downstream of EGFR 
concomitantly with NRG-1-induced ErbB4 activation, c-Src associates with phospho-Tyr950 and 
phospho-Tyr1056 on 4ICD, thereby decreasing nuclear accumulation of 4ICD and inhibiting an 
increase of H3K9me3 levels. Moreover, 4ICD-induced transcriptional repression of the human 
telomerase reverse transcriptase (hTERT) is inhibited by EGF-EGFR-Src signaling. Thus, our 
findings reveal c-Src-mediated inhibitory regulation of ErbB4 nuclear signaling upon EGFR 
activation. 
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Materials and Methods 
 
Plasmids 
cDNA encoding human ErbB4 CYT-1 subcloned into the pcDNA3.1-Zeo (+) (Ogiso et al., 2002) was 
gifted from S. Yokoyama (RIKEN, Yokohama). To construct the ErbB4 intracellular domain (4ICD, 
residues 676-1308), the Kozak sequence was created by PCR using ErbB4 as a template with 
5’-GTGGTCGACGCCACCATGGTTTATGTTAGAAGGAAGAGCATCAAAAAG-3’ (sense), and 5’- 
GCGACTAGTCGGAGCTGACA-3’ (antisense). The SalI-XbaI fragment of the PCR product was 
subcloned into the XhoI-XbaI site of pcDNA4/TO (Invitrogen). FLAG-HA-NLS (Takahashi et al., 
2009; Aoyama et al., 2011)-fused 4ICD (NLS-4ICD) was generated as follows. 4ICD was amplified 
by PCR using ErbB4 as a template with 
5’-GCTGGTCGACTTAGAAGGAAGAGCATCAAAAAGAAAAGAGCCTTG-3’ (sense), and 
5’-GCGACTAGTCGGAGCTGACA-3’ (antisense), and the SalI-XbaI fragment of the PCR product 
was introduced into the XhoI-XbaI site of pcDNA4/TO-NLS-Lyn-HA (Takahashi et al., 2009), 
resulting in the insertion sequence V-L-D-P-A-Q-W-R-P-R-L between the NLS and 4ICD. 
NLS-4ICD was amplified by PCR using 
5’-GAAGTCGACATGTCTTCTGATGATGAAGCTACTGC-3’ (sense) and 
5’-GGAGCTGACACGGAAGATCAACGGCGCCGGCGCAAC-3’ (antisense). The SalI-NotI 
fragment of the PCR product was introduced into the XhoI-NotI site of pOZ-FHN (Nakatani and 
Ogryzko, 2003; provided by A. Iwama, Chiba University). The sequence L-D-G-G-Y-P was inserted 
between the FLAG and HA epitopes, and the sequence G-G-L-A was inserted between the HA 
epitope and the NLS. The resulting FHN-NLS-4ICD was subcloned into pcDNA4/TO. The 
LysArg mutation at position 751 in the ATP-binding site [kinase-dead (KD), K751R] was 
generated by site-directed mutagenesis using FHN-NLS-4ICD as a template with 
5’-GGGACCAGTTGTCTCATTAAGAATTCTAATAGCCACAGGAATCTTCAC-3’ (sense) and 
5’-GTGAAGATTCCTGTGGCTATTAGAATTCTTAATGAGACAACTGGTCCC-3’ (antisense). The 
TyrPhe mutation at position 1056 (4ICD-Y1056F) was created by PCR using 4ICD as a template 
with 5’-GACACAGCCCTCCGCCGGCCTTCACCCCCATGTCAGGAAACCAGTTTG-3’ (sense) and 
5’-CTGACATGGGGGTGAAGGCCGGCGGAGGGCTGTGTCCAATTTCACTCC-3’ (antisense). The 
TyrPhe mutation at positions 950/1056 (4ICD-Y950F/Y1056F) was created by PCR using 
4ICD-Y1056F as a template with 
17 
 
5’-TCTGCACTATTGACGTCTTCATGGTCATGGTCAAATGTTGGATGATTG-3’ (sense) and 
5’-TTTGACCATGACCATGAAGACGTCAATAGTGCAGATGGGAGGCTGAGG-3’ (antisense). The 
NLS was added to the N-terminus of Src-HA was subcloned into pcDNA4/TO (Takahashi et al., 
2009). To construct pcDNA4/TOneoR/NLS-4ICD, the XbaI-XbaI fragment of 
pcDNA4/TO/NLS-4ICD was subcloned into pcDNA4/TOneoR (Nakayama et al., 2009). 
pcDNA4/TOneoR/c-Src-HA (c-Src) was constructed as follows. The HindIII-XhoI fragment of 
pcDNA3/c-Src-HA (provided by S. A. Laporte, McGill University) was subcloned into 
pcDNA4/TOneoR. As a mutation was found at position Leu175, the NotI-KpnI fragment was 
replaced with the NotI-KpnI fragment of human wild-type c-Src (Bjorge et al., 1995) (provided by D. 
J. Fujita, University of Calgary). 
 
Antibodies 
The following antibodies were used: phosphotyrosine (pTyr, 4G10; Upstate Biotechnology Inc; 
provided by T. Tamura, National Institute of Infection Diseases, Tokyo, and T. Yoshimoto, Tokyo 
Medical University) (Tamura et al., 2000), HA (12CA5), ErbB4 (C18; Santa Cruz Biotechnology, 
and HFR1; Abcam), EGFR (provided by M.N. Fukuda, Sanford-Burnham Medical Research 
Institute), phosphor-p44/42 MAP kinase Thr202/Tyr204 (pERK1/2, E10; New England Biolabs), 
ERK2 (C-14; Santa Cruz Biotechnology), Src[Y416] (phospho-Src family; BioSource), Src (GD11; 
Millipore), H3K4me3 (ab8580; Abcam), H3K9me3 (ab8898; Abcam), H4K16ac (Sigma-Aldrich), 
H3K27me3 (ab6002; Abcam), lamin A/C (N-18; Santa Cruz Biotechnology), and actin (clone C4; 
CHEMICON International). Horseradish peroxidase (HRP)-conjugated F(ab’)2 fragment of 
anti-mouse IgG, anti-rabbit IgG or anti-goat IgG antibodies were purchased from Amersham 
Biosciences. TRITC-anti-rabbit IgG or anti-mouse IgG (Fc specific), Alexa Fluor 488-anti-mouse 
IgG or anti-rabbit IgG, and Alexa Fluor 647-anti-rabbit IgG secondary antibodies were from 
BioSource International, Sigma-Aldrich and Invitrogen. 
 
Cells and transfection 
COS-1 (Japanese Collection of Research Bioresources, Osaka), T47D (provided by M. Tagawa, 
Chiba Cancer Center Research Institute), and SYF cells (Klinghoffer et al., 1999) were cultured in 
Iscove’s modified Dulbecco’s medium (IMDM) containing 5% fetal bovine serum (FBS). SYF cells 
stably expressing c-Src-wt (SYF/c-Src) were prepared (Takahashi et al., 2009). Cells were 
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transiently transfected with plasmid DNA using polyethlenimine (Fukumoto et al., 2010). For 
growth factor stimulation, T47D cells were starved under low serum conditions [0.05% bovine 
serum (BS)] for 24 hours, or SYF and SYF/c-Src cells transfected with vector or ErbB4 were 
cultured for 8 hours and then starved for 16 hours. Starved cells were treated with none, 20 ng/ml 
NRG-1 (Neuregulin β-1; R&D Systems), 20 ng/ml EGF, or 20 ng/ml NRG-1 plus 20 ng/ml EGF for 
30min under low serum conditions (0.05% BS). A HeLa S3 cell clone expressing NLS-4ICD was 
generated in an inducible manner (HeLa S3/TR/NLS-4ICD), because we could not establish a cell 
line stably expressing NLS-4ICD. HeLa S3/TR (clone A3f5) cells, which stably express the 
tetracycline repressor (TR) (Aoyama et al., 2011), were transfected with pcDNA4/TOneo/NLS-4ICD, 
and cell clones inducibly expressing NLS-4ICD were selected in 500 µg/ml G418. Expression of 
NLS-4ICD was induced for 8 hours by 2 µg/ml doxycycline, a tetracycline derivative. 
 
Inhibitors 
The following inhibitors were used: 20 µM AG1478, 10 µM PP2, 10 µM SU6656, 20 µM U0126, 1 or 
25 µM DAPT, and 100 nM wortmannin. 
 
Immunofluorescence 
Immunofluorescence staining was performed as described (Yamaguchi and Fukuda, 1995; Tada et 
al., 1999; Nakayama and Yamaguchi, 2005; Kasahara et al., 2007b; Ikeda et al., 2008; Takahashi et 
al., 2009; Nakayama et al, 2012). In brief, cells were washed in warmed phosphate-buffered saline 
(PBS) and fixed in 100% methanol for 5 min at -20ºC (Ni et al., 2001; Aoyama et al., 2011). Fixed 
cells were permeabilized and blocked in PBS containing 0.1% saponin and 3% bovine serum 
albumin for 20 min at room temperature, and then incubated with a primary and a secondary 
antibody for 1 hour each at room temperature. For DNA staining, cells were subsequently treated 
with 200 µg/ml RNase A for 30 min and 20 µg/ml propidium iodide (PI) or 20 nM TOPRO-3 for 30 
min at room temperature. After washing with PBS containing 0.1% saponin, cells were mounted 
with ProLong antifade reagent (Molecular Probes). The resulting red emission of TOPRO-3-stained 
nuclei is pseudo-colored as blue. Confocal and Nomarski differential-interference-contrast (DIC) 
images were obtained at room temperature using a Fluoview FV500 confocal laser scanning 
microscope with a 40× 1.00 NA or a 60× 1.00 water-immersion objective (Olympus, Tokyo) and an 
LSM510 laser scanning microscope with 40× 0.75 NA or 63× 1.40 NA oil immersion objective (Carl 
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Zeiss). One planar (xy) section slice (0.8- or 2.0-µm thickness) was shown in most experiments. 
Composite figures were prepared using Photoshop 11.0 and Illustrator 14.0 software (Adobe). For 
quantitation of histone modifications, confocal images were obtained using a Fluoview FV500 
confocal laser scanning microscope, and then fluorescence intensities of immunostaining were 
measured using ImageJ software (National Institutes of Health). Since two or three independent 
experiments gave similar results, a representative experiment was shown. 
 
Measurement of DNA synthesis using BrdU incorporation 
DNA synthesis was measured by incorporation of bromodeoxyuridine (BrdU) (Roche) into the 
genomic DNA during the S phase (DNA replication) of the cell cycle. T47D cells were starved under 
low serum conditions (0.05% BS) for 24 hours, and then treated with NRG-1 or EGF in the 
presence of BrdU for 24 hours. Cells were fixed with ethanol and 50 mM glycine, pH 2.0, for 45 min 
at room temperature and denaturated in 4 N HCl for 15 min. Subsequent immunodetection of 
BrdU was accomplished, according to the manufacturer’s instructions. 
 
Western blotting and immunoprecipitation 
Cell lysates were prepared in SDS-PAGE sample buffer or Triton X-100 lysis buffer (20 mM 
HEPES, pH 7.8, 5% glycerol, 1% Triton X-100, 5 mM EDTA, 50 mM NaF, 20 mM 
β-glycerophosphate, 50 µg/ml aprotinin, 100 µM leupeptin, 25 µM pepstatin, 10 mM Na3VO4, and 1 
mM PMSF), and subjected to SDS-PAGE and electrotransferred onto polyvinylidene difluoride 
membrane (Millipore). Immunoditection was performed by enhanced chemiluminescence 
(Amersham Biosciences) as described (Yamaguchi et al., 2001; Matsuda et al., 2006; Kasahara et al., 
2007a; Kuga et al., 2007; Ikeda et al., 2008; Sato et al., 2009; Nakayama et al., 2012). Sequential 
reprobing of membranes with a variety of antibodies was performed after the complete removal of 
primary antibodies from membranes in stripping buffer or inactivation of HRP by 0.1% NaN3, 
according to the manufacturer’s instructions. Results were analyzed using a ChemiDoc XRSPlus 
image analyzer (Bio-Rad), and quantitated with Quantity One software (Bio-Rad). 
Immunoprecipitation was performed using antibody-precoated protein-G beads, as described (Mera 
et al., 1999; Yamaguchi et al., 2001; Ikeda et al., 2008; Obata et al., 2010). Composite figures were 
prepared using Photoshop 11.0 and Illustrator 14.0 software (Adobe). 
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Semiquantitative RT-PCR 
Total RNAs were isolated from T47D cells with the ISOGEN reagent (Nippon Gene, Tokyo), and 
cDNAs were synthesized from 1 µg of each RNA preparation using the PrimeScript RT reagent Kit 
(TakaraBio, Shiga) as described (Kikuchi et al., 2010; Aoyama et al., 2011). To avoid saturation of 
PCR products, conditions of PCR were optimized before semiquantitative RT-PCR was carried out. 
The primers used for PCR are as follows: human telomerase reverse transcriptase (hTERT), 
5’-CGGAAGAGTGTCTGGAGCAA-3’ (sense) and 5’-GGATGAAGCGGAGTCTGGA-3’ (antisense) 
(Nakamura et al., 1997); breast cancer 1 (BRCA1), 5’-TTGCGGGAGGAAAATGGGTAGTTA-3’ 
(sense) and 5’-TGTGCCAAGGGTGAATGATGAAAG-3’ (antisense) (Ju et al., 2007); glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), 5’-ACCACAGTCCATGCCATCAC-3’ (sense) and 
5’-TCCACCACCCTGTTGCTGTA-3’ (antisense) (Kikuchi et al., 2010; Aoyama et al., 2011). The 
sizes of PCR products are 146, 292 and 452 bp, respectively. Amplification was carried out using an 
MJ mini thermal cycler (BioRad) with Ex Taq DNA polymerase (TakaraBio, Shiga) under the 
following conditions: For hTERT, initial heating at 95°C for 1 min, followed by 35 cycles of 
denaturation at 95°C for 30 sec, annealing at 56°C for 30 sec and extension at 72°C for 30 sec. For 
BRCA1 and GAPDH, initial heating at 94°C for 2 min, followed by 27 or 25 cycles of denaturation 
at 94°C for 30 sec, annealing at 53°C or 56°C for 30 sec and extension at 72°C for 1 min. The 
products of RT-PCR were electrophoresed on a 2.0 or 3.0% agarose gel containing ethidium bromide. 
The density of each amplified fragment was quantitated with ChemiDoc XRSPlus and Quantity 
One software. 
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Figure legends 
 
Figure 1. Opposing effects of NRG-1 and EGF stimulations on H3K9me3 levels. 
(A) T47D cells were treated with NRG-1 for the indicated times. Cell lysates were analyzed by 
Western blotting using anti-pTyr, anti-ErbB4, and anti-Lamin A/C (loading control) antibodies. The 
position of size markers in kilodaltons (kDa) are shown on the left. (B) T47D cells were treated with 
none or NRG-1 for 30 min and stained with PI for DNA. 2D isometric intensity profiles are shown 
on the lower panels. Spectrum of PI fluorescence intensity from 0 to 255 represents very high (red), 
high (yellow), medium (green), low (blue), and background (black). Scale bars, 10 µm. (C) 
Quantitation of histone modifications. T47D cells treated with none, NRG-1, or EGF for 30 min 
were stained with anti-H3K9me3, anti-H3K4me3, and anti-H4K16ac antibodies (left panels). Scale 
bars, 10 µm. Fluorescence intensities in individual cells are plotted on the right. Numbers in 
parentheses indicate mean values, and bars represent means ± S.D. from a representative 
experiment (n = 40~63 cells). Asterisks indicate the significant difference (***p < 0.001; NS, not 
significant) calculated by Student’s t-test. 
 
Figure 2. Role of nuclear 4ICD in NRG-1-increaed H3K9me3. 
(A) T47D cells were pretreated with none, 1 or 25 µM DAPT for 30 min, and stimulated with 
NGR-1 in the presence or absence of 1 or 25 µM DAPT for 30 min. Cell lysates were analyzed by 
Western blotting, using anti-ErbB4 and anti-Lamin A/C antibodies. (B) T47D cells pretreated with 
AG1478 or 1 µM DAPT for 30 min were stimulated with NRG-1 for 30 min as described in A, and 
then stained with anti-H3K9me3 antibody. Fluorescence intensities of H3K9me3 immunostaining 
were measured as described in Fig. 1C. Scale bars, 10 µm. (C) Schematic representations of the 
constructs used in this study. The extracellular domain (ECD), transmembrane domain (TM), 
intracellular domain (ICD), kinase domain, FLAG-epitope (FLAG), hemagglutinin-epitope (HA), 
nuclear localization signal (NLS), and Src homology (SH) domain are shown. KD, kinase-dead 
(K752R). (D) COS-1 cells transfected with vector alone, 4ICD, or NLS-4ICD were cultured for 48 
hours, and stained with anti-ErbB4 (expressed proteins) and anti-H3K9me3 antibodies. H3K9me3 
levels were quantitated as described in Fig. 1C. Scale bars, 10 µm. (E-G) COS-1 cells transfected 
with the indicated construct were cultured for 48 hours. Cell lysates were analyzed by Western 
blotting using anti-pTyr, anti-ErbB4, anti-HA and anti-actin antibodies. An arrowhead shows a 
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nonspecific band (E). Cells were immunostained with anti-H3K9me3 and anti-HA (expressed 
proteins) antibodies and TOPRO-3 (F), and fluorescence intensities of H3K9me3 and H3K4me3 
were measured as described in Fig. 1C (G). Scale bars, 10 µm. Asterisks indicate the significant 
difference (**p < 0.01; ***p < 0.001; NS, not significant) calculated by Student’s t-test. 
 
Figure 3. Inhibition of NRG-1-increased H3K9me3 by EGF-induced Src activation. 
(A) T47D cells were treated with none, NRG-1, or NRG-1 plus EGF for 30 min, and fluorescence 
intensities of H3K9me3 immunostaining were measured as described in Fig. 1C. Scale bars, 10 µm. 
(B) T47D cells were cultured in IMDM supplemented with 5% fetal bovine serum and the cell 
number was counted (initial cell number). Cells were then treated with none, NRG-1, NRG-1 plus 
EGF, or EGF for the indicated periods in low serum conditions (0.05% bovine serum) with a 
medium change on the 2nd day, and the cell number was counted (top). Results (%) represent 
means ± S.D., n = 3 (2 days) or n = 6 (4 days) independent experiments (bottom). (C) T47D cells 
were treated as described in A, and analyzed by Western blotting using anti-ErbB4, anti-pTyr, 
anti-pERK1/2, anti-ERK2 and anti-Lamin A/C antibodies. (D) T47D cells were treated with none, 
NRG-1 or NRG-1 plus EGF in the presence of DMSO or PP2 for 30 min, and fluorescence 
intensities of H3K9me3 were measured as described in Fig. 1C. Scale bars, 10 µm. (E) (Top) SYF or 
SYF/c-Src cells transfected with ErbB4 were treated with none or NRG-1 for 30 min and stained 
with anti-ErbB4 and anti-H3K9me3 antibodies. (Middle) Fluorescence intensities of ErbB4 
staining were measured (see supplementary material Fig. S5B), and then H3K9me3 levels were 
quantitated in cells exhibiting similar levels of ErbB4 expression as described in Fig. 1C. (Bottom) 
The levels of nuclear localization of ErbB4 were assessed by measuring a ratio of fluorescence 
intensity of anti-ErbB4 staining in the nucleus to that in the corresponding whole cell 
(nucleus/whole cell). The plot represents the level of nuclear localization of ErbB4 in each cell, and 
bars represent means ± S.D., n = 4 independent experiments. N, nucleus; whole, whole cell. Scale 
bars, 10 µm. (F) COS-1 cells transfected with 4ICD plus vector or 4ICD plus c-Src-HA were 
cultured in the presence or absence of SU6656 for 24 hours, and stained with anti-ErbB4 and 
anti-HA (see supplementary material Fig. S5C) antibodies. The areas of nuclei were marked by 
dotted line. N, nucleus; Cyto, cytoplasm. Cells exhibiting N ≥ Cyto localization of 4ICD was 
quantitated, and results (%) represent means ± S.D., n = 3 independent experiments. Scale bars, 10 
µm. Asterisks indicate the significant difference (**p < 0.01; ***p < 0.001; NS, not significant) 
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calculated by Student’s t-test. 
 
Figure 4. Association of c-Src with pTyr950 and pTyr1056 on 4ICD, thereby inhibiting 4ICD’s 
nuclear accumulation and H3K9me3 modification. 
(A) COS-1 cells transfected with 4ICD plus vector or 4ICD plus c-Src-HA were cultured in the presence or 
absence of SU6656 for 24 hours. (Top) Western blotting of equal amounts of TritonX-100 lysates was probed with 
anti-pTyr, anti-ErbB4, anti-Src and anti-actin (loading control) antibodies. (Bottom) 4ICD was immunoprecipitated 
with anti-ErbB4 antibody, and then analyzed by Western blotting using anti-ErbB4, anti-pTyr and anti-Src 
antibodies. The level of 4ICD phosphorylation was quantitated by measuring the signal intensity using anti-pTyr 
antibody and normalized to the corresponding signal intensity detected by anti-ErbB4 antibody, and the amount of 
coimmunoprecipitated c-Src in the presence of SU6656 is expressed as the value relative to that in the absence of 
SU6656. An arrowhead shows a nonspecific band. (B) Schematic representations of 4ICD and its phenylalanine 
mutants at Tyr950 and Tyr1056 are shown. (C, D) COS-1 cells transfected with 4ICD plus vector or each 4ICD 
construct plus c-Src were cultured for 24 hours, and then cell lysates and immunoprecipitates were analyzed as 
described in A. The amounts of co-immunoprecipitated c-Src with 4ICD or its mutants are expressed as values 
relative to those of the 4ICD immunoprecipitate. (D) Cells were stained with anti-ErbB4 antibody, and N ≥ Cyto 
localization of 4ICD was quantitated, as described in Fig. 3F. Results (%) represent means ± S.D., n = 5 
independent experiments. Scale bars, 10 µm. (E) COS-1 cells transfected with vector alone, 4ICD, 4ICD-Y1056F, 
or 4ICD-Y950F/Y1056F were cultured for 48 hours, and stained with anti-ErbB4 (expressed proteins) and 
anti-H3K9me3 antibodies. H3K9me3 levels were quantitated as described in Fig. 1C. Scale bars, 10 µm. Asterisks 
indicate the significant difference (*p < 0.05; **p < 0.01; ***p < 0.001) calculated by Student’s t-test. 
 
Figure 5. Repression of hTERT gene expression by NRG-1, which is blocked by EGF-induced Src 
activation. 
The levels of hTERT and BRCA1 expression were assessed with semiquantitative RT-PCR, and the amounts of 
hTERT and BRCA1 products were quantitated by measuring band intensities and normalizing to the levels of 
GAPDH. (A) T47D cells were treated for 4 days with none, NRG-1, EGF, or NRG-1 plus EGF, as described in Fig. 
3B. Transcriptional expression levels of hTERT were expressed as values relative to those in nontreated cells 
(None). Results represent means ± S.D., n = 4 independent experiments. The position of size markers in base pair 
(bp) are shown on the right. (B) T47D cells were treated for 30 min with the indicated stimulation in the presence 
or absence of SU6656 as described in supplementary material Fig. S5B. The levels of hTERT and BRCA1 were 
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quantitated as described in A. Results represent means ± S.D., n = 5 independent experiments. (C) T47D cells were 
treated with NRG-1 in the presence or absence of 1 µM DAPT for 30 min as described in Fig. 2A, and then 
expression levels of hTERT were quantitated as described in A. Results represent means ± S.D., n = 5 independent 
experiments. (D-G) Parental HeLa S3 cells (None) or HeLa S3 cells expressing NLS-4ICD (NLS-4ICD) were 
cultured for 8 hr, and then stained with anti-ErbB4 and anti-H3K9me3 antibodies. H3K9me3 levels were 
quantitated as described in Fig. 1C. Scale bars, 10 µm (D). (E, F) Cell lysates were analyzed by Western blotting 
using anti-ErbB4, anti-actin, anti-histone H3, anti-H3K9me3 (E), and anti-H3K27me3 (F) antibodies. The level of 
H3K9 or H3K27 tri-methylation was quantitated by measuring the signal intensity using anti-H3K9me3 or 
anti-H3K27me3 antibodies, and normalized to the corresponding signal intensity detected by anti-histone H3 
antibody. (G) Expression levels of hTERT and BRCA1 were expressed as described in A. Results represent means 
± S.D., n = 3 independent experiments. Asterisks indicate the significant difference (*p < 0.05; **p < 0.01; ***p < 
0.001; NS, not significant) calculated by Student’s t-test. 
 
Figure 6. Mechanism of inhibition of NRG-1-mediated ErbB4 signaling by EGF-induced Src activation. 
(A) NRG-1 activates ErbB4 and releases 4ICD from ErbB4. After the release, 4ICD translocates into the nucleus 
thereby increasing H3K9me3 and repressing hTERT gene expression. (B) Costimulation of ErbB4 and EGFR with 
NRG-1 and EGF, respectively. EGF-activated Src associates with pY950 and pY1056 on 4ICD, thereby inhibiting 
nuclear accumulation of 4ICD. Thus, EGFR activation antagonizes the signaling of NRG-1-activated ErbB4 
toward an increase of H3K9me3 and repression of hTERT transcription.  
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Supplemental material 
 
 
Figure S1. NRG-1-indued chromatin structural changes. 
(A, B) T47D cells were treated with none or NRG-1 for 30 min in the presence or absence of AG1478, 
and analyzed by Western blotting (A), using anti-ErbB4, anti-pTyr, anti-pp44/42 MAPK, 
anti-ERK2, and anti-Lamin A/C (loading control) antibodies. (B) T47D cells were stained with 
propidium iodide (PI). A profile displayed at 512 × 512 pixel resolution was taken from the average 
of sixteen scans at the same focal plane. Thickness of one planar (xy) section slice was 0.8 µm. 
Nuclear size was quantitated as the number of pixels in a single nucleus using the ImageJ software. 
Numbers in parentheses indicate mean values, and bars represent means ± S.D. from a 
representative experiment (n = 98~116 cells). Scale bars, 10 µm. Asterisks indicate the significant 
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difference (***p < 0.001) calculated by Student’s t-test. (C) T47D cells were treated with none, 
NRG-1, or EGF for 24 hours, and the number of BrdU-incorporated cells (arrows) was counted on 
10 random microscope fields. Results (%) represent means from two independent experiments. 
Scale bars, 10 µm. (D) T47D cells were treated with EGF for the indicated times, and cell lysates 
were analyzed by Western blotting, using anti-pTyr, anti-EGFR, anti-pp44/42 MAPK, anti-ERK2, 
anti-Src[Y416], anti-Src, and anti-Lamin A/C antibodies. 
 
 
Figure S2. Requirement of ErbB4 in NRG-1-increased H3K9me3 levels. 
(A) COS-1 cells transfected with vector alone or ErbB4 were cultured for 8 hours and then starved for 16 hours 
under low serum conditions (0.05% BS). Starved cells treated with none or NRG-1 for 30 min was stained with 
anti-ErbB4 and anti-H3K9me3 antibodies. H3K9me3 levels quantitated as described in Fig. 1C. Scale bars, 10 µm. 
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Asterisks indicate the significant difference (***p < 0.001; NS, not significant) calculated by Student’s t-test. (B) 
COS-1 cells transfected with the indicated construct were cultured for 48 hours and then stained with anti-pTyr and 
anti-HA (expressed proteins) antibodies and TOPRO-3. Scale bars, 10 µm. 
 
 
 
 
 
 
 
Figure S3. Downregulation of EGFR upon stimulation with EGF but not NRG-1. 
T47D cells were treated for 4 days with none, NRG-1, EGF, or NRG-1 plus EGF, as described in Fig. 3B. Cell 
lysates were analyzed by Western blotting, using anti-EGFR and anti-actin antibodies. 
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Figure S4. Involvement of SFK in EGF-mediated inhibition of H3K9me3 levels. 
(A) T47D cells were treated with none or NRG-1 plus EGF in the presence of DMSO, PP2, U0126, or wortmannin 
for 30 min, and fluorescence intensities of H3K9me3 were measured as described in Fig. 1C. Scale bars, 10 µm. 
(B) T47D cells were treated with none, NRG-1, or NRG-1 plus EGF for 30 min in the presence or absence of 
SU6656, and stained with anti-H3K9me3 antibody. H3K9me3 levels were quantitated as described in Fig. 1C. 
Asterisks indicate the significant difference (***p < 0.001; NS, not significant) calculated by Student’s t-test. 
 
 
Figure S5. Nuclear ErbB4 signaling in SYF and SYF/c-Src cells. 
(A) SYF or SYF/c-Src cells were starved for 16 hours under low serum conditions (0.05% BS). Cell lysates were 
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analyzed by Western blotting, using anti-Src[Y416], anti-Src, and anti-actin antibodies. (B) SYF or SYF/c-Src cells 
transfected with ErbB4 were treated with none or NRG-1 for 30 min and stained with anti-ErbB4 and 
anti-H3K9me3 antibodies, as described in Fig. 3E. Fluorescence intensities of ErbB4 immunostaining were 
measured as described in Fig. 1C, and bars represent means ± S.D., n = 4 independent experiments. NS indicates 
not significant calculated by Student’s t-test. (C) Two dimensional (2D)-plot analyses were performed with the 
results of Fig. 3E [fluorescence intensity of H3K9me3 (Middle) versus nuclear localization level of ErbB4 
(Bottom)]. n, cell number; r, regression coefficient. (D) Localization of c-Src was detected using immunostaining as 
described in Fig. 3F. Scale bars, 10 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. BRCA1 gene expression after 4 days of NRG-1 stimulation. 
T47D cells were treated for 4 days with none, NRG-1, EGF, or NRG-1 plus EGF, as described in Fig. 
3B. Transcriptional expression levels of BRACA1 were expressed as values relative to those in 
nontreated cells (None) as described in Fig. 5A. Results represent means ± S.D., n = 3 independent 
experiments. Asterisks indicate the significant difference (***p < 0.001; NS, not significant) 
calculated by Student’s t-test. 
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Figure S7. Effect of NLS-4ICD on H3K27me3 levels. 
COS-1 cells transfected with vector alone or NLS-4ICD were cultured for 48 hours, and stained with anti-ErbB4 
and anti-H3K27me3 antibodies. H3K27me3 levels were quantitated as described in Fig. 1C. Scale bars, 10 µm. 
Asterisks indicate the significant difference (***p < 0.001; NS, not significant) calculated by Student’s t-test. 
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